Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS)

D Lamichhane; A Weinstein

doi:10.1177/0961203316635287

Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS)

Lupus. 2016 Aug;25(9):1050-3. doi: 10.1177/0961203316635287. Epub 2016 Feb 23.

Authors

D Lamichhane¹, A Weinstein²

Affiliations

¹ Division of Rheumatology, MedStar Washington Hospital Center, Washington, DC, USA.
² Division of Rheumatology, MedStar Washington Hospital Center, Washington, DC, USA Department of Medicine, Georgetown University Medical Center, Washington, DC, USA arthur.weinstein@medstar.net.

PMID: 26911153
DOI: 10.1177/0961203316635287

Abstract

Complement activation is a key feature of systemic lupus erythematosus (SLE). Detection of cell-bound complement activation products (CB-CAPS) occurs more frequently than serum hypocomplementemia in definite lupus. We describe a patient with normocomplementemic probable SLE who did not fulfill ACR classification criteria for lupus, but the diagnosis was supported by the presence of CB-CAPS.

Keywords: Systemic lupus erythematosus (SLE); cell-bound complement activation products (CB-CAPS); complement; neuromyelitis optica (NMO).

Publication types

Case Reports

MeSH terms

Biomarkers / metabolism
Complement Activation*
Complement System Proteins / immunology*
Diagnosis, Differential
Female
Humans
Lupus Erythematosus, Systemic / diagnosis*
Lupus Erythematosus, Systemic / immunology*
Middle Aged

Substances

Biomarkers
Complement System Proteins